Literature DB >> 12373250

Does contrast echocardiography with Optison induce myocardial necrosis in humans?

Adrian C Borges1, Torsten Walde, Rona K Reibis, Andrea Grohmann, Reinhard Ziebig, Wolfgang Rutsch, Ingolf Schimke, Gert Baumann.   

Abstract

Myocardial contrast echocardiography is a promising diagnostic tool for detecting microvascular integrity. Multiple experimental laboratories have shown that diagnostic combined microbubble contrast and ultrasound exposure can cause vessel rupture and myocardial damage in laboratory animals. This study investigated the phenomenon of contrast ultrasonically induced myocardial damage in human beings. Twenty consecutive patients (mean age of 60 +/- 12 years, 14 men) underwent contrast echocardiography with intravenous Optison using a mechanical index of at least 1.4 (Vivid Five System (GE, Vingmed Ultrasound, Horton, Norway). Creatine kinase (CK), creatine kinase-isoenzyme MB (CK-MB); CK-MB mass, myoglobin, and troponin I were measured before and 2, 4, 8, and 24 hours after contrast echocardiography. There was no significant correlation concerning the response to contrast echocardiography for any pair of parameters at any time after the intervention. Only in 2 patients were there higher values for troponin I before and after contrast echocardiography without an increase of myoglobin, CK, or CK-MB mass and activity. These values were therefore interpreted as false positive because of renal failure and severe heart failure. The use of contrast echocardiography is without demonstrated risk of myocardial damage even in patients with different cardiologic entities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373250     DOI: 10.1067/mje.2002.121833

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  9 in total

Review 1.  Novel techniques for assessment of left ventricular systolic function.

Authors:  Sonal Chandra; Hicham Skali; Ron Blankstein
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

Review 2.  Safety of ultrasound contrast agents.

Authors:  Jarl A Jakobsen; Raymond Oyen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2005-01-21       Impact factor: 5.315

3.  Acoustic attenuation by contrast agent microbubbles in superficial tissue markedly diminishes petechiae bioeffects in deep tissue.

Authors:  Ji Song; Alexander L Klibanov; John A Hossack; Richard J Price
Journal:  Invest Radiol       Date:  2008-05       Impact factor: 6.016

Review 4.  [Ultrasound contrast agents. Pharmaceutical drug safety and bioeffects].

Authors:  M Krix; J W Jenne
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

5.  Effects of ultrasound and ultrasound contrast agent on vascular tissue.

Authors:  Steven C Wood; Sible Antony; Ronald P Brown; Jin Chen; Edward A Gordon; Victoria M Hitchins; Qin Zhang; Yunbo Liu; Subha Maruvada; Gerald R Harris
Journal:  Cardiovasc Ultrasound       Date:  2012-07-17       Impact factor: 2.062

6.  Does contrast echocardiography induce increases in markers of myocardial necrosis, inflammation and oxidative stress suggesting myocardial injury?

Authors:  Fabian Knebel; Ingolf Schimke; Stephan Eddicks; Torsten Walde; Reinhard Ziebig; Sebastian Schattke; Gert Baumann; Adrian Constantin Borges
Journal:  Cardiovasc Ultrasound       Date:  2005-08-17       Impact factor: 2.062

Review 7.  Role of intra-operative contrast-enhanced ultrasound (CEUS) in robotic-assisted nephron-sparing surgery.

Authors:  Ahmad N Alenezi; Omer Karim
Journal:  J Robot Surg       Date:  2015-02-07

Review 8.  Combination of contrast with stress echocardiography: a practical guide to methods and interpretation.

Authors:  Stuart Moir; Thomas H Marwick
Journal:  Cardiovasc Ultrasound       Date:  2004-08-26       Impact factor: 2.062

Review 9.  Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery.

Authors:  Vera Paefgen; Dennis Doleschel; Fabian Kiessling
Journal:  Front Pharmacol       Date:  2015-09-15       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.